Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I Study to Assess the Safety of Multiple Doses of CYAD-101, Administered After Standard FOLFOX or FOLFIRI Chemotherapy in Patients With Unresectable Metastatic Colorectal Cancer

NCT03692429 is registered in ClinicalTrials.gov with Celyad Oncology SA as lead sponsor.

NCT NCT03692429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03692429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I Study to Assess the Safety of Multiple Doses of CYAD-101, Administered After Standard FOLFOX or FOLFIRI Chemotherapy in Patients With Unresectable Metastatic Colorectal Cancer
Lead sponsor
Celyad Oncology SA
Phase
Phase 1
Overall status
Recruiting
Start date
November 28, 2018
Completion date
February 17, 2036
Enrollment
49 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable metastatic colorectal cancer